Orwin succeeds Topper as AnaptysBio’s chair
Plus: CDMOs Catalent and Rentschler announce executive changes, and updates from Parexel, Santander, CorriXR and more
John Orwin will succeed Jamie Topper as chairman of AnaptysBio Inc. (NASDAQ:ANAB), which is developing two checkpoint agonists in autoimmune and inflammatory diseases. Orwin, who is on the boards of Seagen Inc. (NASDAQ:SGEN), Travere Therapeutics Inc. (NASDAQ:TVTX) and Cargo Therapeutics Inc., is president and CEO of Atreca Inc. (NASDAQ:BCEL). AnaptysBio added that Topper will serve in an advisory role through 1Q24.
CDMO Rentschler Biopharma SE named Benedikt von Braunmuehl as CEO and Tom Roberts as president of Rentschler Biopharma Inc. and general manager U.S. von Braunmuehl was CEO of HMNC Holding GmbH, which he transformed from a research-focused organization to a clinical-stage biopharma company; Roberts was chairman and acting CEO at Vitanova Biomedical Inc. ...